This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by King, M. K. Articles by Spinale, F. G. Search for Related Content PubMed PubMed Citation Articles by King, M. K. Articles by Spinale, F. G. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Failure Related Collections Structure Congestive Cardiovascular Pharmacology Animal models of human disease

(Circulation. 2001;103:308.)
© 2001 American Heart Association, Inc.

Basic Science Reports

Treatment With a Growth Hormone Secretagogue in a Model of Developing Heart Failure

Effects on Ventricular and Myocyte Function

Mary K. King, DVM; David M. Gay, BS; Lydia C. Pan, PhD; James H. McElmurray, III, BS; Jennifer W. Hendrick, BA; Christine Pirie, MS; Allison Morrison, BS; Connie Ding, MS; Rupak Mukherjee, PhD; Francis G. Spinale, MD, PhD

From the Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, and Cardiovascular and Metabolic Disease, Pfizer Central Research, Groton, Conn (L.C.P., C.P.).

Correspondence to Francis G. Spinale, MD, PhD, Cardiothoracic Surgery, Room 625, Strom Thurmond Research Building, 770 MUSC Complex, Medical University of South Carolina, 114 Doughty St, Charleston, SC 29425.

{abs}Background—Exogenous administration of growth hormone (GH) and subsequently increased production of insulin-like growth factor-1 can influence left ventricular (LV) myocardial growth and geometry in the setting of congestive heart failure (CHF). This study determined the effects of an orally active GH secretagogue (GHS) treatment that causes a release of endogenous GH on LV function and myocyte contractility in a model of developing CHF.

Methods and Results—Pigs were randomly assigned to the following treatment groups: (1) chronic rapid pacing at 240 bpm for 3 weeks (n=11); (2) chronic rapid pacing and GHS (CP-424,391 at 10 mg·kg^-1·d^-1, n=9); and (3) sham controls (n=8). In the untreated pacing CHF group, LV fractional shortening was reduced (21±2% versus 47±2%) and peak wall stress increased (364±21 versus 141±5 g/cm²) from normal control values (P<0.05). In the GHS group, LV fractional shortening was higher (29±2%) and LV peak wall stress lower (187±126 g/cm²) than untreated CHF values (P<0.05). With GHS treatment, the ratio of LV mass to body weight increased by 44% from untreated values. Steady-state myocyte velocity of shortening was reduced with pacing CHF compared with controls (38±1 versus 78±1 µm/s, P<0.05) and was increased from pacing CHF values with GHS treatment (55±7 µm/s, P<0.05).

Conclusions—The improved LV pump function that occurred with GHS treatment in this model of CHF was most likely a result of favorable effects on LV myocardial remodeling and contractile processes. On the basis of these results, further studies are warranted to determine the potential role of GH secretagogues in the treatment of CHF.

Key Words: ventricles • myocytes • contractility • growth substances

This article has been cited by other articles:

				G. P. Zaloga Ghrelin, Diet, and Pulmonary Function Chest, September 1, 2005; 128(3): 1084 - 1086. [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				F. Pecker Ghrelin in the heart and growth hormone: which is chicken, which is egg? Cardiovasc Res, June 1, 2004; 62(3): 442 - 443. [Full Text] [PDF]

				M. Iwase, H. Kanazawa, Y. Kato, T. Nishizawa, F. Somura, R. Ishiki, K. Nagata, K. Hashimoto, K. Takagi, H. Izawa, et al. Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters Cardiovasc Res, January 1, 2004; 61(1): 30 - 38. [Abstract] [Full Text] [PDF]

				A. Torsello, E. Bresciani, G. Rossoni, R. Avallone, G. Tulipano, D. Cocchi, I. Bulgarelli, R. Deghenghi, F. Berti, and V. Locatelli Ghrelin Plays a Minor Role in the Physiological Control of Cardiac Function in the Rat Endocrinology, May 1, 2003; 144(5): 1787 - 1792. [Abstract] [Full Text] [PDF]

				G. Baldanzi, N. Filigheddu, S. Cutrupi, F. Catapano, S. Bonissoni, A. Fubini, D. Malan, G. Baj, R. Granata, F. Broglio, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT J. Cell Biol., December 23, 2002; 159(6): 1029 - 1037. [Abstract] [Full Text] [PDF]

				I. Ahmet, Y. Sawa, K. Iwata, and H. Matsuda Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: A novel gene therapy for cardiomyopathy J. Thorac. Cardiovasc. Surg., November 1, 2002; 124(5): 957 - 963. [Abstract] [Full Text] [PDF]